9: Antimicrobial Drugs - Biology

9: Antimicrobial Drugs - Biology

We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

Chapter 9 BSC 3271 Learning Outcomes

  • Tell the story of the discovery of antibiotics, including who discovered antibiotics, when, how, and the name of the first antibiotic discovered.
  • Define antibiotic and identify the specific group of microbes targeted by antibiotics.
  • Identify major targets of antibiotics and explain why disruption of each will cause microbial death or inactivation.
  • Describe desirable features of an antibiotic that would be used to treat infection.
  • Analyze a situation to identify the most suitable antibiotic/chemotherapy choice.
  • Explain the possible natural role of antibiotics in the environment and give an example of one bacterial genus that produces many clinically relevant antibiotics.
  • Describe the mode of action of beta-lactam antibiotics, including cellular structure impaired, what enzyme is inhibited and how that leads to impairment of cellular structure, consequences of impaired cellular structure, and whether growing cells are more easily killed or not and why.
  • Identify the cellular targets of the following antimicrobial drugs: beta-lactams, aminoglycosides, polymyxins, azoles, nucleotide analogs, and quinolones and which microbial groups they target (broad range, narrow range, which group(s) if narrow range) (which ones?).
  • Know to which class of antimicrobial drugs penicillins, cephalosporins, carbapenems, streptomycin, colistin, fluconazole, acyclovir, and ciprofloxacin belong (beta-lactam, aminoglycoside, azole, polymyxin, or quinolone).
  • By its name, determine if an antibiotic is a penicillin, cephalosporin, or carbapenem.
  • By its name, determine whether an antibiotic is produced by Streptomyces
  • Explain the five common mechanisms of antibiotic resistance.
  • Describe the mechanism of beta-lactamase, including what kind of antibiotics this enzyme provides resistance to, how it provides resistance, and how the compound clavulanic acid counteracts beta-lactamase.
  • Explain why Pseudomonas species are naturally resistant to many different antibiotics.
  • Explain how natural selection leads to the emergence of antibiotic resistant strains of microbes.
  • List several human-controlled factors that contribute to the emergence of antibiotic resistance, including how antibiotics are used in health care and in agriculture.
  • Recognize the following abbreviations of antibiotic resistant pathogens and what the abbreviations stand for: MRSA, VRSA, VRE, CRE, MDR-TB, XDR-TB.
  • Describe strategies to reduce the spread of antibiotic resistance that can be used by 1. health care workers and 2. individuals.
  • Describe viral replication of HIV and how the replication mechanism can result in the development of drug resistance, particularly in the case of the nucleotide analog AZT.
  • Explain how the major anti-HIV drugs work and the advantages to using combination drug therapy.
  • 9.1: Discovering Antimicrobial Drugs
    Antimicrobial drugs produced by purposeful fermentation and/or contained in plants have been used as traditional medicines in many cultures for millennia. The purposeful and systematic search for a chemical “magic bullet” that specifically target infectious microbes was initiated by Paul Ehrlich in the early 20th century. The discovery of the natural antibiotic, penicillin, by Alexander Fleming in 1928 started the modern age of antimicrobial discovery and research.
  • 9.2: Clinical Considerations
    Antimicrobial drugs can be bacteriostatic or bactericidal, and these characteristics are important considerations when selecting the most appropriate drug. The use of narrow-spectrum antimicrobial drugs is preferred in many cases to avoid superinfection and the development of antimicrobial resistance. Broad-spectrum antimicrobial use is warranted for serious systemic infections when there is no time to determine the causative agent or when narrow-spectrum antimicrobials fail.
  • 9.3: Antibiotics
    Antibacterial compounds exhibit selective toxicity, largely due to differences between prokaryotic and eukaryotic cell structure. Cell wall synthesis inhibitors, including the β-lactams, the glycopeptides, and bacitracin, interfere with peptidoglycan synthesis, making bacterial cells more prone to osmotic lysis. There are a variety of broad-spectrum, bacterial protein synthesis inhibitors that selectively target the prokaryotic 70S ribosome, including those that bind to the 30S and 50S subunits.
  • 9.4: Drugs Targeting Other Pathogens
    Because fungi, protozoans, and helminths are eukaryotic organisms like human cells, it is more challenging to develop antimicrobial drugs that specifically target them. Similarly, it is hard to target viruses because human viruses replicate inside of human cells.
  • 9.5: Antibiotic Resistance
    Antimicrobial resistance is on the rise and is the result of selection of drug-resistant strains in clinical environments, the overuse and misuse of antibacterials, the use of subtherapeutic doses of antibacterial drugs, and poor patient compliance with antibacterial drug therapies. Drug resistance genes are often carried on plasmids or in transposons that can undergo vertical transfer easily and between microbes through horizontal gene transfer.
    • 9.5.1: Cost and Prevention of Resistance
    • 9.5B: Antibiotic Misuse
    • 9.5D: Biofilms, Persisters, and Antibiotic Tolerance
    • 9.5E: Finding New Antimicrobial Drugs
  • 9.6: Testing Drug Effectivenes
    The Kirby-Bauer disk diffusion test helps determine the susceptibility of a microorganism to various antimicrobial drugs. However, the zones of inhibition measured must be correlated to known standards to determine susceptibility and resistance, and do not provide information on bactericidal versus bacteriostatic activity, or allow for direct comparison of drug potencies. Antibiograms are useful for monitoring local trends in antimicrobial resistance/susceptibility.

Thumbnail: Staphylococcus aureus - Antibiotics Test plate. (Public Domain; CDC / Provider: Don Stalons).

Targeting virulence: a new paradigm for antimicrobial therapy

Clinically significant antibiotic resistance has evolved against virtually every antibiotic deployed. Yet the development of new classes of antibiotics has lagged far behind our growing need for such drugs. Rather than focusing on therapeutics that target in vitro viability, much like conventional antibiotics, an alternative approach is to target functions essential for infection, such as virulence factors required to cause host damage and disease. This approach has several potential advantages including expanding the repertoire of bacterial targets, preserving the host endogenous microbiome, and exerting less selective pressure, which may result in decreased resistance. We review new approaches to targeting virulence, discuss their advantages and disadvantages, and propose that in addition to targeting virulence, new antimicrobial development strategies should be expanded to include targeting bacterial gene functions that are essential for in vivo viability. We highlight both new advances in identifying these functions and prospects for antimicrobial discovery targeting this unexploited area.

Cell biology of microbes and pharmacology of antimicrobial drugs explored by Atomic Force Microscopy

Antimicrobial molecules have been used for more than 50 years now and are the basis of modern medicine. No surgery can nowdays be imagined to be performed without antibiotics dreadful diseases like tuberculosis, leprosis, siphilys, and more broadly all microbial induced diseases, can be cured only through the use of antimicrobial treatments. However, the situation is becoming more and more complex because of the ability of microbes to adapt, develop, acquire, and share mechanisms of resistance to antimicrobial agents. We choose to introduce this review by briefly drawing the panorama of antimicrobial discovery and development, but also of the emergence of microbial resistance. Then we describe how Atomic Force Microscopy (AFM) can be used to provide a better understanding of the mechanisms of action of these drugs at the nanoscale level on microbial interfaces. In this section, we will address these questions: (1) how does drug treatment affect the morphology of single microbes? (2) do antimicrobial molecules modify the nanomechanical properties of microbes, or do the nanomechanical properties of microbes play a role in antimicrobial activity and efficiency? and (3) how are the adhesive abilitites of microbes affected by antimicrobial drugs treatment? Finally, in a second part of this review we focus on recent studies aimed at changing the paradigm of the single molecule/cell technology that AFM typically represents. Recent work dealing with the creation of a microbe array which can be explored by AFM will be presented, as these developments constitute the first steps toward transforming AFM into a higher throughput technology. We also discuss papers using AFM as NanoMechnanicalSensors (NEMS), and demonstrate the interest of such approaches in clinical microbiology to detect quickly and with high accuracy microbial resistance.

Keywords: AFM Bacteria assembly Bacterial adhesion MEMS Microbial cell wall Nanoechanic Single cell Single molecule.

9: Antimicrobial Drugs - Biology

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited.

Feature Papers represent the most advanced research with significant potential for high impact in the field. Feature Papers are submitted upon individual invitation or recommendation by the scientific editors and undergo peer review prior to publication.

The Feature Paper can be either an original research article, a substantial novel research study that often involves several techniques or approaches, or a comprehensive review paper with concise and precise updates on the latest progress in the field that systematically reviews the most exciting advances in scientific literature. This type of paper provides an outlook on future directions of research or possible applications.

Editor’s Choice articles are based on recommendations by the scientific editors of MDPI journals from around the world. Editors select a small number of articles recently published in the journal that they believe will be particularly interesting to authors, or important in this field. The aim is to provide a snapshot of some of the most exciting work published in the various research areas of the journal.

Development and Challenges of Antimicrobial Peptides for Therapeutic Applications

More than 3000 antimicrobial peptides (AMPs) have been discovered, seven of which have been approved by the U.S. Food and Drug Administration (FDA). Now commercialized, these seven peptides have mostly been utilized for topical medications, though some have been injected into the body to treat severe bacterial infections. To understand the translational potential for AMPs, we analyzed FDA-approved drugs in the FDA drug database. We examined their physicochemical properties, secondary structures, and mechanisms of action, and compared them with the peptides in the AMP database. All FDA-approved AMPs were discovered in Gram-positive soil bacteria, and 98% of known AMPs also come from natural sources (skin secretions of frogs and toxins from different species). However, AMPs can have undesirable properties as drugs, including instability and toxicity. Thus, the design and construction of effective AMPs require an understanding of the mechanisms of known peptides and their effects on the human body. This review provides an overview to guide the development of AMPs that can potentially be used as antimicrobial drugs.

Keywords: FDA-approved peptides antibiotic resistance antibiotics antimicrobial peptides peptide therapeutics rational protein design.


Abed, N., Sa໽-Hassane, F., Zouhiri, F., Mougin, J., Nicolas, V., Desmaële, D., et al. (2015). An efficient system for intracellular delivery of beta-lactam antibiotics to overcome bacterial resistance. Sci. Rep. 5:13500. doi: 10.1038/srep13500

Adrio, J. L., and Demain, A. L. (2006). Genetic improvement of processes yielding microbial products. FEMS Microbiol. Rev. 30, 187�. doi: 10.1111/j.1574-6976.2005.00009.x

Alper, H., Fischer, C., Nevoigt, E., and Stephanopoulos, G. (2005). Tuning genetic control through promoter engineering. Proc. Natl. Acad. Sci. U.S.A. 102, 12678�. doi: 10.1073/pnas.0504604102

Anthouard, R., and DiRita, V. J. (2015). Chemical biology applied to the study of bacterial pathogens. Infect. Immun. 83, 456�. doi: 10.1128/IAI.02021-14

Anyaogu, D. C., and Mortensen, U. H. (2015). Heterologous production of fungal secondary metabolites in Aspergilli. Front. Microbiol. 6:77. doi: 10.3389/fmicb.2015.00077

Atanasov, A. G., Waltenberger, B., Pferschy-Wenzig, E. M., Linder, T., Wawrosch, C., Uhrin, P., et al. (2015). Discovery and resupply of pharmacologically active plant-derived natural products: a review. Biotechnol. Adv. 33, 1582�. doi: 10.1016/j.biotechadv.2015.08.001

Berdy, J. (2005). Bioactive microbial metabolites. J. Antibiot. 58, 1�. doi: 10.1038/ja.2005.1

Bertrand, S., Bohni, N., Schnee, S., Schumpp, O., Gindro, K., and Wolfender, J. L. (2014). Metabolite induction via microorganism co-culture: a potential way to enhance chemical diversity for drug discovery. Biotechnol. Adv. 32, 1180�. doi: 10.1016/j.biotechadv.2014.03.001

Butler, M. S., Robertson, A. A., and Cooper, M. A. (2014). Natural product and natural product derived drugs in clinical trials. Nat. Prod. Rep. 31, 1612�. doi: 10.1039/C4NP00064A

Chemler, J. A., and Koffas, M. A. (2008). Metabolic engineering for plant natural product biosynthesis in microbes. Curr. Opin. Biotechnol. 19, 597�. doi: 10.1016/j.copbio.2008.10.011

Conrado, R. J., Wu, G. C., Boock, J. T., Xu, H., Chen, S. Y., Lebar, T., et al. (2012). DNA-guided assembly of biosynthetic pathways promotes improved catalytic efficiency. Nucleic Acids Res. 40, 1879�. doi: 10.1093/nar/gkr888

Delebecque, C. J., Lindner, A. B., Silver, P. A., and Aldaye, F. A. (2011). Organization of intracellular reactions with rationally designed RNA assemblies. Science 333, 470�. doi: 10.1126/science.1206938

Demain, A. L., and Sanchez, S. (2009). Microbial drug discovery: 80 years of progress. J. Antibiot. 62, 5�. doi: 10.1038/ja.2008.16

Dhakal, D., Chaudhary, A. K., Yi, J. S., Pokhrel, A. R., Shrestha, B., Parajuli, P., et al. (2016). Enhanced production of nargenicin A1 and creation of a novel derivative using a synthetic biology platform. Appl. Microbiol. Biotechnol. 100, 9917�. doi: 10.1007/s00253-016-7705-3

Dhakal, D., Le, T. T., Pandey, R. P., Jha, A. K., Gurung, R., Parajuli, P., et al. (2015). Enhanced production of nargenicin A1 and generation of novel glycosylated derivatives. Appl. Biochem. Biotechnol. 175, 2934�. doi: 10.1007/s12010-014-1472-3

Dhakal, D., and Sohng, J. K. (2015). Commentary: toward a new focus in antibiotic and drug discovery from the Streptomyces arsenal. Front. Microbiol. 6:727. doi: 10.3389/fmicb.2015.00727

Dueber, J. E., Wu, G. C., Malmirchegini, G. R., Moon, T. S., Petzold, C. J., Ullal, A. V., et al. (2009). Synthetic protein scaffolds provide modular control over metabolic flux. Nat. Biotechnol. 27, 753�. doi: 10.1038/nbt.1557

Galanie, S., Thodey, K., Trenchard, I. J., Interrante, M. F., and Smolke, C. D. (2015). Complete biosynthesis of opioids in yeast. Science 349, 1095�. doi: 10.1126/science.aac9373

Goers, L., Freemont, P., and Polizzi, K. M. (2014). Co-culture systems and technologies: taking synthetic biology to the next level. J. R. Soc. Interface 11:20140065. doi: 10.1098/rsif.2014.0065

Gomez-Escribano, J. P., and Bibb, M. J. (2011). Engineering Streptomyces coelicolor for heterologous expression of secondary metabolite gene clusters. Microb. Biotechnol. 4, 207�. doi: 10.1111/j.1751-7915.2010.00219.x

Goss, R. J., Shankar, S., and Fayad, A. A. (2012). The generation of “unnatural” products: synthetic biology meets synthetic chemistry. Nat. Prod. Rep. 29, 870�. doi: 10.1039/c2np00001f

Gurunathan, S., Han, J. W., Kwon, D. N., and Kim, J. H. (2014). Enhanced antibacterial and anti-biofilm activities of silver nanoparticles against Gram-negative and Gram-positive bacteria. Nanoscale Res. Lett. 9:373. doi: 10.1186/1556-276X-9-373

Harvey, A. L., Edrada-Ebel, R., and Quinn, R. J. (2015). The re-emergence of natural products for drug discovery in the genomics era. Nat. Rev. Drug Discov. 14, 111�. doi: 10.1038/nrd4510

Harvey, C. J., Puglisi, J. D., Pande, V. S., Cane, D. E., and Khosla, C. (2012). Precursor directed biosynthesis of an orthogonally functional erythromycin analogue: selectivity in the ribosome macrolide binding pocket. J. Am. Chem. Soc. 134, 12259�. doi: 10.1021/ja304682q

Hayashi, M. A., Bizerra, F. C., and Da-Silva, P. I. (2013). Antimicrobial compounds from natural sources. Front. Microbiol. 4:195. doi: 10.3389/fmicb.2013.00195

Hong, J. (2011). Role of natural product diversity in chemical biology. Curr. Opin. Chem. Biol. 15, 350�. doi: 10.1016/j.cbpa.2011.03.004

Jha, A. K., Dhakal, D., Van, P. T. T., Pokhrel, A. R., Yamaguchi, T., Jung, H. J., et al. (2015). Structural modification of herboxidiene by substrate-flexible cytochrome P450 and glycosyltransferase. Appl. Microbiol. Biotechnol. 99, 3421�. doi: 10.1007/s00253-015-6431-6

Keasling, J. D. (2012). Synthetic biology and the development of tools for metabolic engineering. Metab. Eng. 14, 189�. doi: 10.1016/j.ymben.2012.01.004

Kennedy, J. (2008). Mutasynthesis, chemobiosynthesis, and back to semi-synthesis: combining synthetic chemistry and biosynthetic engineering for diversifying natural products. Nat. Prod. Rep. 25, 25�. doi: 10.1039/B707678A

Kim, E., Moore, B. S., and Yoon, Y. J. (2015). Reinvigorating natural product combinatorial biosynthesis with synthetic biology. Nat. Chem. Biol. 11, 649�. doi: 10.1038/nchembio.1893

Kirschning, A., Taft, F., and Knobloch, T. (2007). Total synthesis approaches to natural product derivatives based on the combination of chemical synthesis and metabolic engineering. Org. Biomol. Chem. 5, 3245�. doi: 10.1039/b709549j

Kolter, R., and van Wezel, G. P. (2016). Goodbye to brute force in antibiotic discovery? Nat. Microbiol. 1:15020. doi: 10.1038/nmicrobiol.2015.20

Komatsu, M., Komatsu, K., Koiwai, H., Yamada, Y., Kozone, I., Izumikawa, M., et al. (2013). Engineered Streptomyces avermitilis host for heterologous expression of biosynthetic gene cluster for secondary metabolites. ACS Synth. Biol. 2, 384�. doi: 10.1021/sb3001003

Koryakina, I., Kasey, C., McArthur, J. B., Lowell, A. N., Chemler, J. A., et al. (2016). Inversion of extender unit selectivity in the erythromycin polyketide synthase by acyltransferase domain engineering. ACS. Chem. Biol. 12, 114�. doi: 10.1021/acschembio.6b00732

Lam, S. J., Oɻrien-Simpson, N. M., Pantarat, N., Sulistio, A., Wong, E. H., Chen, Y. Y., et al. (2016). Combating multidrug-resistant Gram-negative bacteria with structurally nanoengineered antimicrobial peptide polymers. Nat. Microbiol. 1:16162. doi: 10.1038/nmicrobiol.2016.162

Lee, J. W., Na, D., Park, J. M., Lee, J., Choi, S., and Lee, S. Y. (2012). Systems metabolic engineering of microorganisms for natural and non-natural chemicals. Nat. Chem. Biol. 8, 536�. doi: 10.1038/nchembio.970

Lee, S. H., Wang, H., Labroli, M., Koseoglu, S., Zuck, P., Mayhood, T., et al. (2016). TarO-specific inhibitors of wall teichoic acid biosynthesis restore β-lactam efficacy against methicillin-resistant staphylococci. Sci. Transl. Med. 8, 329ra32. doi: 10.1126/scitranslmed.aad7364

Li, Y., Li, Z., Yamanaka, K., Xu, Y., Zhang, W., Vlamakis, H., et al. (2015). Directed natural product biosynthesis gene cluster capture and expression in the model bacterium Bacillus subtilis. Sci. Rep. 5:9383. doi: 10.1038/srep09383

Ling, L. L., Schneider, T., Peoples, A. J., Spoering, A. L., Engels, I., Conlon, B. P., et al. (2015). A new antibiotic kills pathogens without detectable resistance. Nature 517, 455�. doi: 10.1038/nature14098

Luo, Y., Li, B. Z., Liu, D., Zhang, L., Chen, Y., Jia, B., et al. (2015). Engineered biosynthesis of natural products in heterologous hosts. Chem. Soc. Rev. 44, 5265�. doi: 10.1039/C5CS00025D

Medema, M. H., Breitling, R., Bovenberg, R., and Takano, E. (2011). Exploiting plug-and-play synthetic biology for drug discovery and production in microorganisms. Nat. Rev. Microbiol. 9, 131�. doi: 10.1038/nrmicro2478

Medema, M. H., van Raaphorst, R., Takano, E., and Breitling, R. (2012). Computational tools for the synthetic design of biochemical pathways. Nat. Rev. Microbiol. 10, 191�. doi: 10.1038/nrmicro2717

Meneguetti, B. T., MacHado, L. D., Oshiro, K. G., Nogueira, M. L., Carvalho, C. M., and Franco, O. L. (2016). Antimicrobial peptides from fruits and their potential use as biotechnological tools- a review and outlook. Front. Microbiol. 7:2136. doi: 10.3389/fmicb.2016.02136

Newman, D. J., and Cragg, G. M. (2012). Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311�. doi: 10.1021/np200906s

Nielsen, D. R., and Moon, T. S. (2013). From promise to practice, the role of synthetic biology in green chemistry. EMBO Rep. 14, 1034�. doi: 10.1038/embor.2013.178

Nielsen, J., Fussenegger, M., Keasling, J., Lee, S. Y., Liao, J. C., Prather, K., et al. (2014). Engineering synergy in biotechnology. Nat. Chem. Biol. 10, 319�. doi: 10.1038/nchembio.1519

Nyerges, Á., Csörgő, B., Nagy, I., Bálint, B., Bihari, P., Lázár, V., et al. (2016). A highly precise and portable genome engineering method allows comparison of mutational effects across bacterial species. Proc. Natl. Acad. Sci. U.S.A. 113, 2502�. doi: 10.1073/pnas.1520040113

Pimentel-Elardo, S. M., Sørensen, D., Ho, L., Ziko, M., Bueler, S. A., Lu, S., et al. (2015). Activity-independent discovery of secondary metabolites using chemical elicitation and cheminformatic inference. ACS Chem. Biol. 10, 2616�. doi: 10.1021/acschembio.5b00612

Polpass, A. J., and Jebakumar, S. R. D. (2013). Non-streptomycete actinomycetes nourish the current microbial antibiotic drug discovery. Front. Microbiol. 4:240. doi: 10.3389/fmicb.2013.00240

Porro, D., Branduardi, P., Sauer, M., and Mattanovich, D. (2014). Old obstacles and new horizons for microbial chemical production. Curr. Opin. Biotechnol. 30, 101�. doi: 10.1016/j.copbio.2014.06.009

Ross, A. C., Gulland, L. E., Dorrestein, P. C., and Moore, B. S. (2014). Targeted capture and heterologous expression of the Pseudoalteromonas alterochromide gene cluster in Escherichia coli represents a promising natural product exploratory platform. ACS Synth. Biol. 4, 414�. doi: 10.1021/sb500280q

Salis, H. M., Mirsky, E. A., and Voigt, C. A. (2009). Automated design of synthetic ribosome binding sites to control protein expression. Nat. Biotechnol. 27, 946�. doi: 10.1038/nbt.1568

Singh, P., Kim, Y. J., Wang, C., Mathiyalagan, R., El-Agamy Farh, M., and Yang, D. C. (2016). Biogenic silver and gold nanoparticles synthesized using red ginseng root extract, and their applications. Artif. Cells Nanomed. Biotechnol. 44, 811�. doi: 10.3109/21691401.2015.1008514

Stephanopoulos, G. (2012). Synthetic biology and metabolic engineering. ACS Synth. Biol. 1, 514�. doi: 10.1021/sb300094q

Stephanopoulos, G., and Vallino, J. J. (1991). Network rigidity and metabolic engineering in metabolite overproduction. Science 252, 1675�. doi: 10.1126/science.1904627

Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., and Xia, Y. (2014). Engineered nanoparticles for drug delivery in cancer therapy. Angew. Chem. Int. Ed. Engl. 53, 12320�. doi: 10.1002/anie.201403036

Wang, H., Gill, C. J., Lee, S. H., Mann, P., Zuck, P., Meredith, T. C., et al. (2013). Discovery of wall teichoic acid inhibitors as potential anti-MRSA β-lactam combination agents. Chem. Biol. 20, 272�. doi: 10.1016/j.chembiol.2012.11.013

Wang, H., Russa, M. L., and Qi, L. S. (2016). CRISPR/Cas9 in genome editing and beyond. Annu. Rev. Biochem. 85, 227�. doi: 10.1146/annurev-biochem-060815-014607

Weissman, K. J. (2007). Mutasynthesis-uniting chemistry and genetics for drug discovery. Trends Biotechnol. 25, 139�. doi: 10.1016/j.tibtech.2007.02.004

Winn, M., Fyans, J. K., Zhuo, Y., and Micklefield, J. (2016). Recent advances in engineering nonribosomal peptide assembly lines. Nat. Prod. Rep. 33, 317�. doi: 10.1039/C5NP00099H

Xie, X., Tao, Q., Zou, Y., Zhang, F., Guo, M., Wang, Y., et al. (2011). PLGA nanoparticles improve the oral bioavailability of curcumin in rats: characterizations and mechanisms. J. Agric. Food Chem. 59, 9280�. doi: 10.1021/jf202135j

Yamazaki, H., Rotinsulu, H., Narita, R., Takahashi, R., and Namikoshi, M. (2015). Induced Production of halogenated epidithiodiketopiperazines by a marine-derived Trichoderma cf. brevicompactum with sodium halides. J. Nat. Prod. 78, 2319�. doi: 10.1021/acs.jnatprod.5b00669

Yan, Y., Chen, J., Zhang, L., Zheng, Q., Han, Y., Zhang, H., et al. (2013). Multiplexing of combinatorial chemistry in antimycin biosynthesis: expansion of molecular diversity and utility. Angew. Chem. Int. Ed. Engl. 52, 12308�. doi: 10.1002/anie.201305569

Yu, K., Liu, C., Kim, B. G., and Lee, D. Y. (2015). Synthetic fusion protein design and applications. Biotechnol. Adv. 33, 155�. doi: 10.1016/j.biotechadv.2014.11.005

Zhang, H., Wang, Y., Wu, J., Skalina, K., and Pfeifer, B. A. (2010). Complete biosynthesis of erythromycin A and designed analogs using E. coli as a heterologous host. Chem. Biol. 17, 1232�. doi: 10.1016/j.chembiol.2010.09.013

Ziemert, N., Alanjary, M., and Weber, T. (2016). The evolution of genome mining in microbes𠄺 review. Nat. Prod. Rep. 33, 988�. doi: 10.1039/C6NP00025H

Zipperer, A., Konnerth, M. C., Laux, C., Berscheid, A., Janek, D., Weidenmaier, C., et al. (2016). Human commensals producing a novel antibiotic impair pathogen colonization. Nature 535, 511�. doi: 10.1038/nature18634

Keywords: antimicrobial drugs, biological engineering, synthetic biology, chemical synthesis methods, metabolic engineering

Citation: Dhakal D and Sohng JK (2017) Coalition of Biology and Chemistry for Ameliorating Antimicrobial Drug Discovery. Front. Microbiol. 8:734. doi: 10.3389/fmicb.2017.00734

Received: 03 January 2017 Accepted: 10 April 2017
Published: 04 May 2017.

Tzi Bun Ng, The Chinese University of Hong Kong, Hong Kong

Anjan Debnath, University of California, San Diego, USA
Ayush Kumar, University of Manitoba, Canada
Ahmed A. Al-Amiery, National University of Malaysia, Malaysia

Copyright © 2017 Dhakal and Sohng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Watch the video: Παρουσίαση Δρ Μαρκέλλας Μάρκου Αντιβιοτικά και αντιμικροβιακή ανθεκτικότητα (October 2022).